The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- Sanofi’s Prostate Cancer Drug Cabazitaxel Gets Japan OK
July 7, 2014
- MTPC’s SGLT-2 Inhibitor Canaglu Wins Japan Approval
July 7, 2014
- European Commission Approves Expanded Indication for Halaven for Earlier Use in Breast Cancer Treatment: Eisai
July 7, 2014
- Nippon Kayaku Obtains Approval for Remicade Biosimilar
July 7, 2014
- Sawai Preparing to File More Products for US Approval: Exec
July 4, 2014
- Santen to Complete Acquisition of Ophthalmology Assets from Merck
July 4, 2014
- Taiho Submits Application for Additional Indication of Febrile Neutropenia for Zosyn
July 4, 2014
- BMKK Asks Major Law Firm to Conduct Independent Investigation of Clinical Research on Sprycel
July 4, 2014
- Kyowa Kirin to Resume Development of Bardoxolone Methyl for CKD Patients with Type 2 Diabetes
July 4, 2014
- Poteligeo Re-Filed for Approval of Additional Indication of Untreated CCR4-Positive ATL
July 3, 2014
- Meiji Seika Pharma Wants to Make Cancer Drugs, Biologics 4th Biz Pillar
July 3, 2014
- Genzyme Japan Submits NDA for Oral Gaucher’s Disease Drug
July 3, 2014
- CMIC, JSR Set Up Joint Venture for Next-Generation Antibodies
July 3, 2014
- MTPC Plans Entry into Global Vaccine Business Starting with a Seasonal Influenza Vaccine
July 3, 2014
- Hospira Japan Appoints Former Mundipharma President Toyohara as Its New President
July 3, 2014
- Sawai, MTPC Agree on Transfer of Kashima Plant to Sawai
July 3, 2014
- Takeda Sets Up Japan Vaccine Unit Led by Ex-Sanofi R&D Head
July 2, 2014
- Pfizer Japan to Diversify Revenue Streams to Maintain Growth in “Post-Lipitor Era”: President
July 2, 2014
- Sumitomo Dainippon Transfers Marketing Rights to 3 Brands Including Inteban to Teikoku Seiyaku
July 2, 2014
- Sanofi Ties Up with Japanese Bioventure for Development of Transdermal Patch Formulation of Lyxumia
July 2, 2014
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…